Ignite Creation Date:
2025-12-24 @ 2:49 PM
Ignite Modification Date:
2026-02-11 @ 2:15 AM
Study NCT ID:
NCT02431559
Status:
COMPLETED
Last Update Posted:
2022-10-10
First Post:
2015-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-12-02
Start Date Type:
ACTUAL
Primary Completion Date:
2018-12-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-10
Completion Date Type:
ACTUAL
First Submit Date:
2015-04-27
First Submit QC Date:
None
Study First Post Date:
2015-05-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-07
Results First Submit QC Date:
None
Results First Post Date:
2019-09-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-03
Last Update Post Date:
2022-10-10
Last Update Post Date Type:
ACTUAL